Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22264554 | 0.76 | NQO2 (0.37) | ESR1ESR2RAB9AGABRA1GABRB2 | |
| SCHEMBL1336497 | 0.72 | KDM4E (0.43) | RAB9ALMNAPOLBGAASMN1; SMN2 | |
| SCHEMBL4148466 | 0.71 | MEN1 (0.44) | LMNASMN1; SMN2 | |
| SCHEMBL31128303 | 0.71 | NQO2 (0.39) | ESR1ESR2LMNAVRK1 | |
| SCHEMBL14183028 | 0.71 | GPR35 (0.43) | HSP90AA1POLBGAASMN1; SMN2ALOX15 | |
| SCHEMBL12806791 | 0.69 | BACE1 (0.45) | ESR1ESR2HSP90AA1GABRA1GABRB2 | |
| SCHEMBL16736759 | 0.68 | MCL1 (0.44) | ESR1ESR2HSP90AA1MCL1BACE1 | |
| SCHEMBL24249176 | 0.68 | VRK1 (0.30) | ALOX15VRK1 | |
| SCHEMBL21607084 | 0.68 | KDM4E (0.37) | ESR1ESR2HSP90AA1LMNAGAA | |
| SCHEMBL24253381 | 0.68 | RPS6KA3 (0.36) | GABRA1GABRB2LMNATSHRVRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | ESR1 3126/4885ESR2 2082/4885HSP90AA1 2130/4885 |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | ESR1 2825/4885ESR2 1662/4885HSP90AA1 2009/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | ESR1 2825/4885ESR2 1662/4885HSP90AA1 2009/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | ESR1 2825/4885ESR2 1662/4885HSP90AA1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.